Clinical Fellowships
Supports U.S. academic institutions in training physicians and advancing research in Transthyretin (ATTR) Amyloidosis through multidisciplinary clinical fellowships.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships full application)
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds support salary and fellow benefits only.
Summary: Supports U.S. academic institutions in advancing physician training and research in Transthyretin (ATTR) Amyloidosis through clinical fellowship grants.
Key Information: Only ACGME-accredited institutions with active Cardiology Fellowship Programs are eligible; funds are awarded to institutions, not individuals.
Description
Alnylam Pharmaceuticals provides Clinical Fellowship Grants to U.S. academic healthcare organizations to support educational clinical programs focused on Transthyretin (ATTR) Amyloidosis. The goal is to advance physician training in diagnosis, treatment, and research of ATTR amyloidosis, fostering multidisciplinary collaboration to improve early recognition, optimize care pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. The program is strictly for institutions (not individuals) and emphasizes comprehensive, multidisciplinary training and research engagement.
